Pediatric Urinary Tract Infections

• Bacterial adherence and uropathogenic mechanisms: The initiating event in UTI pathogenesis is bacterial colonization of the urothelium via type 1 and P (pili-associated) fimbriae expressed by uropathogenic Escherichia coli (UPEC), the causative organism in >80% of community-acquired pediatric UTIs. Type 1 fimbriae mediate adherence to mannose-containing uroplakins on superficial umbrella cells lining the bladder epithelium, allowing bacterial internalization and intracellular biofilm formation that protects organisms from antibiotics and immune attack. P fimbriae specifically recognize the Gal-Gal linkage on P blood group glycoproteins expressed on uroepithelial cells and renal tubular epithelium, enabling preferential colonization of upper urinary tract structures; children with nonsecretor phenotypes (who lack P antigen expression) have reduced UTI susceptibility. Once established within the urothelium, bacteria trigger toll-like receptor (TLR-4, TLR-5) signaling through lipopolysaccharide and flagellin recognition, activating nuclear factor-κB (NF-κB) pathways that promote production of pro-inflammatory cytokines (IL-6, IL-8, TNF-α) and neutrophil chemokines, resulting in pyuria that characterizes active infection.

• Host immune defenses and developmental immaturity: The pediatric innate immune system demonstrates developmental limitations in antimicrobial defenses compared to adults, including reduced baseline complement activation, immature neutrophil chemotaxis and bactericidal capacity (particularly impaired in infants <6 months), and lower concentrations of urinary immunoglobulin A (IgA) and lysozyme that normally provide mucosal defense. The neonatal and infant immune system exhibits a Th2-predominant bias that gradually shifts toward Th1/Th17 responses necessary for intracellular bacterial control; this developmental transition correlates with the dramatic increase in UTI incidence in the first 6 months of life. Additionally, children have quantitatively lower urinary antimicrobial peptides (lactoferrin, defensins) and reduced organic acid concentrations that normally maintain urinary acidity hostile to bacterial survival. The incomplete maturation of interferon-γ (IFN-γ) responses in young children particularly impairs intracellular killing of bacteria within macrophages and epithelial cells, explaining increased susceptibility to severe infections including urosepsis in this age group.

• Anatomic and functional risk factors specific to childhood: The pediatric urinary tract has unique anatomic characteristics that promote infection: the shorter female urethra (3-4 cm in girls vs. 20 cm in boys) provides minimal barrier to ascending infection, and the periurethral flora in girls includes gram-negative enterobacteria at higher densities than in women. Vesicoureteral reflux (VUR), present in 30-45% of children with febrile UTI and up to 80% in those with recurrent infections, permits retrograde flow of infected urine to the renal parenchyma, bypassing normal ureteral peristalsis and increasing risk of pyelonephritis and renal scarring. Dysfunctional voiding patterns common in young children—including infrequent or incomplete bladder emptying, severe constipation with fecal impaction, and abdominal straining—lead to elevated intravesical pressures, incomplete washout of bacterial inoculum, and increased urine residual volumes that facilitate bacterial proliferation. Neurogenic dysfunction (spina bifida, tethered spinal cord) disrupts normal voiding physiology and impairs bladder compliance, creating chronic elevated pressures and residual urine. The immature ureteral musculature in young children (<1 year) shows diminished peristaltic amplitude and frequency, reducing the mechanical clearance of bacteria from the collecting system.

• Renal parenchymal injury and scarring mechanisms: In pyelonephritis, bacterial LPS and inflammatory mediators (TNF-α, IL-1β, IL-6) activate interstitial immune cells including macrophages and T lymphocytes, triggering intense local inflammation with recruitment of polymorphonuclear leukocytes (PMNs) into renal tubules and interstitium. This inflammatory response, while necessary for bacterial clearance, causes direct tissue injury through reactive oxygen species (ROS) generation, protease release, and complement deposition; paradoxically, children with the most robust inflammatory responses (reflected by higher plasma procalcitonin and CRP) have greatest risk for renal scarring. The scarring process involves fibroblast activation, increased tissue inhibitors of metalloproteinases (TIMPs) relative to matrix metalloproteinases (MMPs), and excessive collagen deposition in the renal interstitium and cortex, occurring over 3-6 months after acute infection. Permanent renal scarring is demonstrable on DMSA scintigraphy in 15-40% of children with acute pyelonephritis, with highest rates in those <4 years old, in those with delayed treatment, and in those with high-grade VUR (grades III-V). The scarring leads to progressive nephron loss, focal glomerulosclerosis in remaining glomeruli, and activation of the renin-angiotensin-aldosterone system (RAAS), predisposing affected children to hypertension (present in 5-10% of children with renal scarring) and chronic kidney disease in adolescence and adulthood.

• **Uropathogenic Escherichia coli (UPEC)**: Accounts for 80-90% of community-acquired pediatric UTIs and gram-negative bacteremia in UTI with sepsis. The prevalence of UPEC increases with age; in neonates, non-UPEC gram-negative organisms (Klebsiella, Enterobacter, Proteus) and gram-positive organisms (Enterococcus, Group B Streptococcus) represent a larger proportion of infections, reflecting differences in host susceptibility and periurethral colonization patterns. UPEC strains associated with pyelonephritis possess specific virulence factors (P fimbriae, hemolysin production, aerobactin) that enable upper tract invasion; strains causing cystitis typically express type 1 fimbriae and produce cytotoxic necrotizing factor (CNF-1), which disrupts cytoskeletal organization in epithelial cells.

• Vesicoureteral reflux (VUR): Present in 30-50% of children presenting with febrile UTI and up to 80% of those with recurrent UTIs, representing the single most important anatomic risk factor for renal involvement. Primary VUR results from congenital incomplete development of the ureteroveisical junction (UVJ) with shortened intramural ureter and inadequate muscularization of the submucosal tunnel; this anatomic deficiency permits passive retrograde urine flow during bladder filling or voiding, depending on reflux grade. Secondary VUR occurs in the setting of elevated bladder outlet resistance (posterior urethral valves in boys, tight external sphincter contraction in dysfunctional voiding) or diminished bladder compliance (neurogenic bladder, severe constipation). The clinical significance of VUR in promoting pyelonephritis is evidenced by the observation that children with grade III-V reflux (involving the renal pelvis and calyces) have pyelonephritis rates of 30-50% with each febrile UTI, compared to 5-10% in children without VUR.

• Dysfunctional voiding and constipation: Present in 20-40% of children with recurrent UTI, characterized by failure to relax the external urethral sphincter during micturition (disynergia), resulting in elevated detrusor pressures, incomplete emptying, and urine residual volumes of 20-50% or higher of total bladder capacity. Constipation represents an independent risk factor affecting 50-75% of children with recurrent UTI; fecal impaction increases intra-abdominal pressure, compresses the bladder and urethra, and alters periurethral flora composition toward increased gram-negative bacteria. The mechanism linking constipation to UTI involves both mechanical effects (incomplete bladder emptying, increased post-void residual) and microbial effects (altered fecal microbiota with proliferation of uropathogenic species). Clinical studies demonstrate that aggressive treatment of constipation with polyethylene glycol and behavioral modification reduces recurrent UTI incidence by 50-70% in affected children.

• Female sex and short female urethra: Girls have 3-5 fold higher UTI incidence than boys after the neonatal period, with cumulative prevalence of 3-5% by age 10 years in girls compared to 1% in boys. The anatomic basis relates to the shorter female urethra (3-4 cm vs. 20 cm in males), minimal natural antibacterial properties, and proximity to the anus with risk of periurethral contamination with fecal flora. Additionally, the female urethra lacks the prostatic secretions (containing zinc, citrate, and antimicrobial peptides) present in males that contribute to antibacterial defense. Girls with recurrent UTIs show higher vaginal and periurethral colonization with uropathogenic bacteria and reduced vaginal colonization with protective lactobacilli, suggesting altered local microbiota ecology.

• Age <5 years, particularly infants and toddlers: Infants <6 months have the highest UTI incidence (1-2%), with peak incidence at 1-3 months of age; this age group has immature innate immunity, increased susceptibility to gram-negative bacteremia, and higher rates of serious associated infections (bacteremia in 10-15%, meningitis in 1-3%). Children aged 1-4 years continue to have elevated UTI incidence (0.5-1% annually) due to developmental limitations in immune responses and voiding control. After age 5 years, UTI incidence declines substantially, correlating with maturation of immune responses and achievement of voluntary urinary control.

• Anatomic urologic abnormalities: Obstructive uropathy (including ureteropelvic junction obstruction, vesicoureteral obstruction, and posterior urethral valves in boys) increases infection risk through stasis and elevated intraluminal pressures. Neurogenic bladder (spina bifida, tethered spinal cord, sacral agenesis) causes incomplete emptying, elevated post-void residuals, and abnormal detrusor function, with UTI prevalence of 25-50% in this population. Renal dysplasia, hypoplasia, and duplicated collecting systems carry increased infection risk through anatomic abnormalities in urine flow mechanics.

• Neonatal-specific risk factors: Male sex (paradoxically protective after neonatal period but associated with higher infection rates in neonates), uncircumcision (relative risk 3-7 for UTI in uncircumcised boys in some studies, though controversy exists), prematurity (<34 weeks gestation), low birth weight (<1500 g), and maternal peripartum infections increase neonatal UTI risk. Prenatal factors including maternal urinary tract infections, oligohydramnios, and abnormal prenatal ultrasound findings suggesting fetal renal abnormalities identify high-risk pregnancies.

• Immunocompromise and genetic predisposition: Children with genetic immunodeficiencies (complement deficiencies C3, C5-C8; IgA deficiency; asplenia) have increased infection rates and severity. Familial clustering of recurrent UTI suggests genetic predisposition related to innate immune polymorphisms (TLR-4 variants) and bacterial adhesion molecules (ABO blood group nonsecretor status, FUT2 polymorphisms).

• Fever: Present in 70-90% of children with pyelonephritis and 20-30% with cystitis, though may be absent in 10-20% of young infants with UTI (particularly those <3 months old). The fever in pyelonephritis is typically sustained and may be high-grade (>39°C), contrasting with the lower-grade fevers sometimes seen in isolated cystitis. Fever alone without localizing symptoms is the presenting complaint in 50% of febrile infants with UTI, making empiric urinalysis and culture mandatory in all febrile infants <2 years without an obvious alternative source of infection. The pathophysiology of fever relates to bacterial endotoxin-stimulated release of pyrogenic cytokines (IL-1, TNF-α, IL-6) from activated monocytes and macrophages, which reset the hypothalamic temperature set-point.

• Dysuria, frequency, and urgency: Classic symptoms reported by toilet-trained children and recognized by older toddlers as discomfort during voiding; presence indicates lower urinary tract involvement (cystitis) but does not exclude concurrent pyelonephritis. Frequency and urgency reflect bladder irritation from inflammatory mediators and bacterial products triggering C-fiber afferent activity in the bladder mucosa. Young children may present with behavioral manifestations including regression (return to daytime incontinence in previously continent children), behavioral changes during voiding (squatting, holding genitals), or acute-onset incontinence. The absence of dysuria does not exclude UTI, particularly in infants and young toddlers who cannot verbalize discomfort, and does not differentiate cystitis from pyelonephritis.

• Suprapubic or abdominal pain: Localized suprapubic discomfort indicates bladder involvement (cystitis) and results from inflammatory activation of visceral pain fibers in the bladder wall. Non-specific abdominal pain without localizing features may accompany both cystitis and pyelonephritis in young children; severe flank or costovertebral angle (CVA) pain is highly suggestive of pyelonephritis but is uncommon in infants and young toddlers who cannot localize discomfort.

• Nausea, vomiting, and anorexia: Present in 30-50% of children with pyelonephritis, reflecting systemic symptoms of infection and renal parenchymal inflammation; vomiting may be prominent enough to cause dehydration, particularly in infants. These symptoms may overshadow urinary tract symptoms, leading to misdiagnosis of gastroenteritis unless urinalysis is obtained. The mechanism involves bacterial endotoxins and inflammatory cytokines stimulating the chemoreceptor trigger zone and affecting appetite centers.

• Irritability, lethargy, and sepsis-like presentations: Nonspecific presentation in infants and young toddlers with UTI, reflecting systemic inflammatory response to bacterial infection; 10-15% of febrile infants with UTI have concurrent bacteremia with gram-negative organisms. Severe presentations including septic shock, altered mental status, hypotension, and disseminated intravascular coagulation (DIC) can occur, particularly in infants <3 months old and those with structural urinary tract abnormalities. Occult bacteremia rates in febrile infants with UTI approach 5-10%, making blood cultures essential in infants and young children with signs of systemic toxicity.

• Jaundice: Occurs in 5-10% of neonates and young infants with UTI, resulting from unconjugated hyperbilirubinemia related to increased hemolysis (from endotoxin-induced hemolysis and sepsis) and decreased hepatic conjugation capacity in neonates. This presentation may lead to initial misdiagnosis as hemolytic disease or physiologic jaundice unless UTI screening is performed.

• Failure to thrive and poor feeding: Infants with chronic or recurrent UTI may present with poor weight gain, feeding difficulties, and

Step 1 — obtain an uncontaminated specimen

• Catheterization or suprapubic aspiration: The American Academy of Pediatrics (AAP) 2011 guideline (reaffirmed 2016) for febrile infants 2–24 months requires that both urinalysis and culture be obtained from a catheterized or suprapubically aspirated specimen before antibiotics. A bag specimen has an unacceptable false-positive rate from periurethral flora; a negative bag urinalysis can help exclude UTI, but a positive one must never be used to diagnose it.
• Midstream clean-catch is acceptable only in reliably toilet-trained, continent children.

Step 2 — urinalysis (the initial, rapid test)

• Leukocyte esterase: released by lysed neutrophils; the most sensitive dipstick marker of pyuria.
• Nitrite: the most specific marker, because Enterobacterales reduce dietary nitrate to nitrite — but it requires several hours of bladder incubation, so it is frequently negative in infants who void often, and is absent with Enterococcus, Staphylococcus saprophyticus, and Pseudomonas, which lack nitrate reductase.
• Microscopy: pyuria (conventionally ≥5 WBC/hpf on spun urine, or ≥10 WBC/µL on enhanced uncentrifuged urinalysis) plus bacteriuria on Gram stain. WBC casts localize infection to the renal parenchyma (pyelonephritis).

Step 3 — culture is the gold standard

• AAP requires both pyuria/bacteriuria on urinalysis and ≥50,000 CFU/mL of a single uropathogen on a catheterized specimen. Pyuria without growth is sterile pyuria; growth without pyuria usually reflects asymptomatic bacteriuria or contamination and does not warrant treatment.

Step 4 — imaging

• Renal and bladder ultrasound after a first febrile UTI in every child 2–24 months (AAP), looking for hydronephrosis, duplication, or obstruction.
• VCUG is not routine after a first febrile UTI; it is reserved for abnormal ultrasound, recurrent febrile UTI, or atypical/severe illness, and it both grades vesicoureteral reflux (I–V) and diagnoses posterior urethral valves (dilated posterior urethra in a male infant).
• DMSA scintigraphy is the reference standard for acute pyelonephritis and permanent cortical scarring but is not part of routine workup.

Immediate assessment and stabilization

• Toxic-appearing or septic child: isotonic crystalloid resuscitation, blood culture, and prompt parenteral antibiotics. Per the AAP 2021 febrile infant guideline, infants 8–21 days old with fever receive full evaluation including lumbar puncture, hospitalization, and parenteral antibiotics; neonates with UTI have meaningful rates of concurrent bacteremia and meningitis.

First-line antimicrobial therapy

• Third-generation cephalosporins (cefixime or cefdinir orally; ceftriaxone or cefotaxime parenterally) are the usual empiric choice in infants and children beyond the neonatal period, chosen for reliable Enterobacterales coverage and renal parenchymal penetration.
• Ampicillin plus an aminoglycoside (gentamicin) is standard in neonates, covering Enterococcus, group B Streptococcus, and Listeria. Ceftriaxone is avoided in neonates because it displaces bilirubin from albumin (kernicterus risk) and precipitates with calcium-containing fluids.
• Route: The AAP states oral therapy is as effective as parenteral for children who can tolerate PO and are not toxic; parenteral therapy is for vomiting, dehydration, young infants, or ill appearance, with step-down to oral once afebrile and improving. Narrow therapy to culture and susceptibility results.
• Duration: AAP recommends a 7–14 day course for febrile UTI/pyelonephritis; shorter courses are reserved for afebrile cystitis in older children.

Escalation and definitive management

• **Resistant organisms (ESBL-producing E. coli, Klebsiella)**: carbapenem therapy guided by susceptibilities; fluoroquinolones are second-line in children given cartilage/tendon toxicity concerns.
• Failure to defervesce in ~48–72 hours: repeat imaging for renal abscess or obstructive pyonephrosis, which requires urgent drainage.
• Surgical/procedural: valve ablation for posterior urethral valves; endoscopic subureteric bulking agent injection or ureteral reimplantation for high-grade VUR with breakthrough febrile UTIs or progressive scarring.
• Antimicrobial prophylaxis: the RIVUR trial showed trimethoprim-sulfamethoxazole prophylaxis reduced recurrent febrile UTI in children with VUR without clearly reducing scarring, and increased resistant organisms — so its use is selective, not universal.

Contraindicated or avoided

• Nitrofurantoin for febrile UTI/pyelonephritis — it concentrates in urine but not renal parenchyma or blood.
• Sulfonamides and ceftriaxone in neonates (kernicterus).
• Treating asymptomatic bacteriuria, which promotes resistance without benefit.

Emergencies

• Urosepsis and gram-negative bacteremia: endotoxin-driven cytokine release causes vasodilatory shock; signals are hypotension, delayed capillary refill, lethargy, and lactic acidosis in a febrile infant. Highest risk under 3 months of age.
• Bacterial meningitis in the neonate: hematogenous seeding from urinary source; any ill-appearing febrile neonate with UTI needs CSF evaluation per the AAP febrile infant guideline.
• Obstructive pyonephrosis / renal or perinephric abscess: pus under pressure behind an obstructed ureteropelvic or ureterovesical junction. Suspect when fever persists beyond ~48–72 hours of appropriate antibiotics; requires imaging and urgent decompression or drainage — antibiotics alone are insufficient.
• Posterior urethral valves with obstructive uropathy: a male infant with a weak urinary stream, palpable bladder, bilateral hydronephrosis, and rising creatinine needs immediate bladder drainage.

Delayed and chronic complications

• Renal cortical scarring: neutrophil-derived reactive oxygen species and proteases injure tubules, followed by interstitial fibrosis over months. Detected as focal photopenic defects on DMSA scan; strongly associated with delayed treatment, young age, and high-grade VUR.
• Hypertension: scarred, hypoperfused segments activate the renin-angiotensin-aldosterone axis — the reason children with known scarring need periodic blood pressure checks.
• Chronic kidney disease and proteinuria: nephron loss drives hyperfiltration in surviving glomeruli and secondary focal segmental glomerulosclerosis; new proteinuria in a child with reflux nephropathy is the warning sign.
• Struvite (magnesium ammonium phosphate) calculi: urease-producing Proteus mirabilis alkalinizes urine; look for a staghorn calculus with persistently alkaline pH.

Complications of treatment

• Aminoglycosides: proximal tubular accumulation causes non-oliguric acute kidney injury; cochlear hair-cell damage causes irreversible sensorineural hearing loss.
• Ceftriaxone: biliary sludging/pseudolithiasis; kernicterus in neonates via bilirubin displacement.
• Trimethoprim-sulfamethoxazole: Stevens-Johnson syndrome, hyperkalemia, marrow suppression; chronic prophylaxis selects resistant uropathogens.
• Any antibiotic: Clostridioides difficile colitis.
• VCUG: catheterization discomfort, iatrogenic infection, and gonadal radiation exposure.

• Fever without a source in an infant = get a urinalysis and culture. In a child under 24 months with unexplained fever, the single best next step is a catheterized urine specimen for both UA and culture. A bag specimen is the classic wrong answer — it is only useful when negative.
• Nitrite is specific, leukocyte esterase is sensitive. A negative nitrite never excludes UTI in an infant: urine must dwell in the bladder for hours to accumulate nitrite, and Enterococcus, S. saprophyticus, and Pseudomonas do not reduce nitrate.
• Diagnosis requires pyuria plus ≥50,000 CFU/mL of a single uropathogen on catheterized specimen (AAP). Growth without pyuria in an asymptomatic child is asymptomatic bacteriuria — do not treat.
• Ultrasound for everyone, VCUG for the selected few. AAP recommends renal-bladder ultrasound after a first febrile UTI in children 2–24 months; VCUG is reserved for an abnormal ultrasound or a second febrile UTI. Reflexively ordering VCUG after the first infection is the commonest distractor.
• DMSA is the gold standard for scarring, not ultrasound and not VCUG — VCUG grades reflux, DMSA grades parenchymal damage.
• The association examiners love: high-grade VUR (III–V) → recurrent pyelonephritis → cortical scarring → hypertension and CKD. Reflux itself is silent; the infection causes the damage.
• Nitrofurantoin is wrong for febrile UTI. It achieves urinary but not renal parenchymal or serum levels — useless for pyelonephritis and for bacteremia.
• Neonatal caveats: ceftriaxone is avoided in neonates (bilirubin displacement → kernicterus, calcium precipitation); ampicillin plus gentamicin is the classic pairing, covering Enterococcus and group B Streptococcus alongside E. coli.
• Buzzword links: urease-positive Proteus → alkaline urine and struvite staghorn calculus; weak stream with bilateral hydronephrosis in a male infant → posterior urethral valves; sterile pyuria → think Kawasaki disease, adenoviral cystitis, urethritis, or renal tuberculosis.